FDA Approves Durolane to Treat Knee Osteoarthritis Pain

This article originally appeared here.
Share this content:
Bioventus plans to launch Durolane, which has been available in over 25 countries for more than 15 years, in the US in early 2018.
Bioventus plans to launch Durolane, which has been available in over 25 countries for more than 15 years, in the US in early 2018.

The Food and Drug Administration (FDA) has approved Durolane for the treatment of pain associated with knee osteoarthritis. Durolane is a single-injection, hyaluronic acid (HA) product used for joint lubrication.

In clinical trials, treatment with Durolane effectively relieved pain and restored function for up to 6 months in patients with knee osteoarthritis.

Bioventus plans to launch Durolane, which has been available in over 25 countries for more than 15 years, in the US in early 2018. 

The Company has already launched 2 other products for the treatment of osteoarthritis: 3-injection HA Gelysin-3 and 5-injection HA Supartz FX. 

Reference

Bioventus. Website. https://www.bioventusglobal.com/. Accessed September 2017.

You must be a registered member of Rheumatology Advisor to post a comment.